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Enzyme inhibitionAbstract In this study a series of pyrazole-3,4-dicarboxamide (3–10) derivatives bearing sulfon-
amide moiety were synthesized starting from 1-(3-nitrophenyl)-5-phenyl-1H-pyrazole-3,4-
dicarboxylic acid (1). The structures of synthesized molecules were characterized by FT-IR, 1H
NMR, 13C NMR, and elemental analysis methods. Human carbonic anhydrase isoenzymes (hCA
I and hCA II) were puriﬁed separately from erythrocyte cells by the Sepharose-4B-L-tyrosine-sulfa
nilamide afﬁnity column chromatography and inhibitory effects of newly synthesized sulfonamides
on esterase activities of these isoenzymes have been studied as in vitro. The Ki values of compounds
were found in the range of 0.056–110.400 lM for hCA I and 0.057–533.400 lM for hCA II.
Compound 4 has the highest inhibitory effect for hCA I and hCA II while compound 5 showed low-
est inhibition. The structure–activity relationships for the inhibition of these isoforms with the
pyrazole-sulfonamides reported here were also elucidated.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Carbonic anhydrases (CAs, EC 4.2.1.1) are a superfamily of
metalloenzymes that catalyze a very simple but essential phys-
iological reaction, carbon dioxide hydration to bicarbonate
and protons (Supuran, 2010, 2012; Alterio et al., 2012;
Gu¨zel-Akdemir et al., 2013; Marini et al., 2012). In mammals,
there are 16 different isoforms of these metalloenzymes among
which several are cytosolic (CA I–III, CA VII and CA XIII),
ﬁve are membrane-bound (CA IV, CA IX, CA XII, CA
XIV, and CA XV), two are mitochondrial (CA VA and VB),
and one (CA VI) is secreted into saliva/milk (Supuran,hydrase
2 S. Mert et al.2008a, 2009; Winum et al., 2009; Supuran et al., 2004; Pastorek
et al., 2008; Hassan et al., 2013; Brzozowski et al., 2010). Three
acatalytic forms (CA VIII, CA X and CA XI) are also known
(Winum et al., 2009; Hen et al., 2011). Among them, human
CA isoforms I and II are the object of major interest as drug-
gable targets for antiglaucoma, anticonvulsants, and diuretics
(Gu¨zel-Akdemir et al., 2013; Supuran, 2008b; Balseven et al.,
2013; Tanc et al., 2013).
Up to now myriad CA inhibitors have been synthesized or
isolated as sulfonamide and non-sulfonamide (such as phenols,
thiols, coumarins, polyamines, and dithiocarbamates) inhibi-
tors (Kasımog˘ulları et al., 2011; Go¨cer et al., 2014; Bilginer
et al., 2014; Akbaba et al., 2013; Carta et al., 2010, 2012,
2013; Almajan et al., 2005; Davis et al., 2013). Therefore, the
synthetic studies continue at a great pace today for the synthe-
sis of new CAIs that have a good inhibitory proﬁle with min-
imal side effects.
Pyrazole compounds are unique molecules and pyrazole-
fused ring systems are found in numerous applications in drug
discovery efforts (Yet, 2008). Pyrazole derivatives exhibit
broad spectrum of biological activities such as analgesic, anti-
inﬂammatory, antipyretic, antibacterial, antifungal, and
antiproliferative (Kuo et al., 1984; Bekhit et al., 2010;
Schegol’kov et al., 2006; Tanitame et al., 2004; Li et al.,
2006; Kostakis et al., 2002). Among them, some are used as
phosphodiesterase inhibitors, COX-2 inhibitors, and CB1
cannabinoid receptors such as Sildenaﬁl, Celecoxib and
Rimonabant, respectively (Terrett et al., 1996; Dale et al.,
2000; Penning et al., 1997; Lan et al., 1999; Francisco et al.,
2002; Katoch-Rouse et al., 2003) (see Fig. 1). In continuation
of our research efforts of the discovery of novel pyrazole-Sildenafil
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et al., 2011; Sen et al., 2013), herein we describe synthesis,
characterization, and evaluation of the inhibition effects of sul-
fonamide bearing pyrazole-3,4-dicarboxamides (3–10) on CA I
and CA II isozymes. We use two free sulfonamide derivatives
(4-aminobenzenesulfonamide and 5-amino-1,3,4-thiadiazole-
2-sulfonamide) and two sterically hindered sulfonamide
derivatives (sulfadiazine and sulﬁsoxazole) in the synthesis of
new inhibitors. And four of our compounds (3–6) have
3-nitrophenyl moiety bonded the ﬁrst position of the pyrazole
ring. We reduced the nitro groups and we obtained four new
derivatives (7–10) which have 3-aminophenyl moiety in same
position (see Scheme 1 and Table 1). Based on this informa-
tion, this article has two main aims. First, we aimed to make
a comparison between the activities of our inhibitors that con-
tain free SO2NH2 groups (3, 4, 7, and 8) and sterically hin-
dered derivatives (4, 5, 9, and 10). Second we aimed to make
a comparison between the activities of the derivatives that have
nitro and amine groups. Third we aimed to discuss the selective
inhibition effects of our compounds on human carbonic anhy-
drase isozymes I and II.
2. Experimental protocols
2.1. Material and methods
The chemicals were purchased from the commercial venders
and the solvents were puriﬁed by using appropriate purifying
agents and distillation. Tetrahydrofuran (THF) was distilled
from sodium/benzophenone prior to use. All reactions were
monitored and purity of the product was checked by analyticalN
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Table 1 Ki values of the compounds (3–10) on the both isoenzymes (CA I and CA II).
Compound
Ki (lM)
R0 R00 CA I CA II
3 ANO2 0.331 0.163
4 ANO2 0.056 0.057
5 ANO2 No inhibition 533.400
6 ANO2 14.283 211.000
7 ANH2 0.306 0.121
8 ANH2 5.108 0.599
9 ANH2 110.400 45.470
10 ANH2 23.940 54.470
Novel pyrazole-3,4-dicarboxamides bearing biologically active sulfonamide moiety 3thin-layer chromatography (TLC) on 0.25 mm precoated
Kieselgel 60F 254 plates (E. Merck Co., Darmstadt,
Germany) and compounds were visualized by TLC devicesPlease cite this article in press as: Mert, S. et al., Novel pyrazole-3,4-dicarboxamides
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solvent system was chloroform/methanol (20:1) for all com-
pounds. Melting points (C, uncorrected) were taken in openbearing biologically active sulfonamide moiety as potential carbonic anhydrase
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4 S. Mert et al.capillaries on a Barnstead Electrothermal 9200 melting point
apparatus (Electrothermal Co, Essex, UK). Infrared (IR) spec-
tra were recorded by Bruker Optics, Vertex 70 Fourier
Transform Infrared Spectrometer (FT-IR) equipped with an
ATR (Attenuated Total Reﬂection) device and the data were
reported in reciprocal centimeters (cm1) (Bruker Optik
GmbH, Ettlingen, Germany). 1H NMR and 13C NMR spectra
were recorded in DMSO-d6 solutions at 298 K using a Bruker
Ultrashield-400 spectrometer operating at 400.00 MHz for 1H
and 101.00 MHz for 13C (Bruker BioSpin GmbH Silberstreifen
D-76287, Rheinstetten, Germany). The center of the peaks of
DMSO-d6 [d (ppm): 2.50 (
1H) and d (ppm): 39.5 (13C)] was
used as an internal reference in a 5-mmNMR tube (Wilmad,
No. 528-PP). Elemental analyses (C, H, N, and S) were per-
formed on a Leco CHNS-932 elemental analyser (LECO
Corporation, Saint Joseph, Michigan, USA).
2.2. Synthesis of target inhibitors
2.2.1. General procedure for the synthesis of pyrazole-3,4-
dicarboxamides (3–6)
A mixture of acid dichloride (2) (1 mmol), and appropriate sul-
fonamide derivative (4 mmol) was heated under reﬂux condi-
tion in freshly distilled THF (30 ml) for 5 h. The solvent was
evaporated in vacuo and residue was washed with water. The
precipitated crude product was ﬁltered and crystallized from
appropriate solvent.
2.2.2. 1-(3-Nitrophenyl)-5-phenyl-N3,N4-bis(5-sulfamoyl-1,3,4-
thiadiazol-2-yl)-1H-pyrazole-3,4-dicarboxamide (3)
Synthesized from 2 (0.39 g, 1 mmol) and 5-amino-1,3,4-thiadia
zole-2-sulfonamide (0.72 g, 4 mmol) according to the general
procedure. The crude product was puriﬁed by crystallization
from ethanol. Yield: 92%; mp: 230–232 C; IR (t, cm1):
3367 and 3280 (NH), 3089 (ArCH), 1654 (C‚O, amide),
1614–1450 (C‚C and C‚N), 1525 and 1351 (NO2), 1378
and 1172 (S‚O); 1H NMR (400 MHz, DMSO-d6) d (ppm):
13.97 (br, s, 2H, 2CONH), 8.37 and 8.35 (s, 4H, 2SO2NH2),
8.43–7.44 (m, 9H, ArH); 13C NMR (101 MHz, DMSO-d6) d
(ppm): 164.80 and 164.57 (C‚O, amide), 161.15, 161.06,
160.79 and 160.72 (thiadiazole C-2 and C-5), 148.87
(CANO2), 147.93 (pyrazole C-3), 146.06 (pyrazole C-5),
120.31 (pyrazole C-4), 143.02, 138.73, 131.18, 130.58, 130.20,
128.76, 126.64, 123.59, 116.88. Anal. Calcd. for
C21H15N11O8S4: C, 37.22; H, 2.23; N, 22.74; S, 18.93;
Found: C, 37.13; H, 2.27; N, 22.81; S, 19.02.
2.2.3. 1-(3-Nitrophenyl)-5-phenyl-N3,N4-bis(4-sulfamoylpheny-
l)-1H-pyrazole-3,4-dicarboxamide (4)
Synthesized from 2 (0.39 g, 1 mmol) and 4-aminobenzene-
sulfonamide (0.69 g, 4 mmol) according to the general proce-
dure. The crude product was puriﬁed by crystallization from
MeOH/H2O (1:1). Yield: 90 %; mp: 227–229 C; IR (t,
cm1): 3254 (NH), 3038 (ArCH), 1628 (C = O, amide),
1591–1483 (C‚C and C‚N), 1526 (NO2), 1316 and 1151
(S‚O); 1H NMR (400 MHz, DMSO-d6) d (ppm): 13.12 and
10.91 (s, 2H, 2CONH), 8.33–7.42 (m, 17H, ArH), 7.31 and
7.28 (s, 4H, 2SO2NH2);
13C NMR (101 MHz, DMSO-d6) d
(ppm): 160.89 and 159.82 (C‚O, amide), 147.90 (CANO2),
144.37 (pyrazole C-3), 144.17 (pyrazole C-5), 120.49 (pyrazole
C-4), 143.59, 141.86, 141.22, 139.16, 139.01, 138.63, 131.70,Please cite this article in press as: Mert, S. et al., Novel pyrazole-3,4-dicarboxamides
inhibitors. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2130.71, 129.80, 128.75, 127.41, 126.72, 126.51, 123.50, 120.32,
120.22, 118.79. Anal. Calcd. for C29H23N7O8S2: C, 52.64; H,
3.50; N, 14.82; S, 9.69; Found: C, 52.70; H, 3.56; N, 14.77;
S, 9.73.
2.2.4. 1-(3-Nitrophenyl)-5-phenyl-N3,N4-bis(4-(N-(pyrimidin-
2-yl)sulfamoyl)phenyl)-1H-pyrazole-3,4-dicarboxamide (5)
Synthesized from 2 (0.39 g, 1 mmol) and sulfadiazine (1 g,
4 mmol) according to the general procedure. The crude pro-
duct was puriﬁed by crystallization from EtOH/DMF (2:1).
Yield: 94%; mp: 149–151 C; IR (t, cm1): 3373 (NH), 3036
(ArCH), 1686 (C‚O, amide), 1625–1435 (C‚C and C‚N),
1532 (NO2), 1343 and 1152 (S‚O);
1H NMR (400 MHz,
DMSO-d6) d (ppm): 11.34 (br, s, 2H, 2SO2NH), 11.14 and
10.94 (s, 2H, 2CONH), 8.54 and 8.51 (d, J= 4.8 Hz,
2 · (2H), 4CH, symmetrical pyrimidine H4 and H6), 8.49–
6.56 (m, 17H, ArH), 7.07–6.99 (m, 2 · (1H), 2CH, symmetrical
pyrimidine H5); 13C NMR (101 MHz, DMSO-d6) d (ppm):
158.34 and 158.22 (C‚O, amide), 157.21 (pyrimidine C2),
156.94 and 153.02 (pyrimidine C4 and C6), 148.09 (CANO2),
147.63 (pyrazole C3), 141.92 (pyrazole C5), 120.20 (pyrazole
C4), 118.29 (pyrimidine C5), 132.26, 131.68, 131.19, 130.81,
130.52, 130.38, 130.29, 129.80, 129.40, 129.05, 128.93, 128.16,
128.04, 127.50, 124.85, 124.39, 121.04. Anal. Calcd. for
C37H27N11O8S2: C, 54.34; H, 3.33; N, 18.84; S, 7.84; Found:
C, 54.29; H, 3.36; N, 18.90; S, 7.88.
2.2.5. N3,N4-bis(4-(N-(3,4-dimethylisoxazol-5-yl)sulfamoyl)p-
henyl)-1-(3-nitrophenyl)-5-phenyl-1H-pyrazole-3,4-dicarboxa-
mide (6)
Synthesized from 2 (0.39 g, 1 mmol) and Sulﬁsoxazole (1.07 g,
4 mmol) according to the general procedure. The crude pro-
duct was puriﬁed by crystallization from MeOH/H2O (3:1).
Yield: 93%; mp: 233–235 C; IR (t, cm1): 3381 and 3359
(NH), 3029 (ArCH), 2980 (Aliphatic CH), 1687 and 1660
(C‚O, amide), 1589–1442 (C‚C and C‚N), 1530 and
1343 (NO2), 1370 and 1158 (S‚O);
1H NMR (400 MHz,
DMSO-d6) d (ppm): 11.19 and 11.02 (s, 2H, 2CONH), 10.99
(br, s, 2H, SO2NH), 8.34–7.42 (m, 17H, ArH), 2.10 (s, 6H,
2CH3(3) isoxazole), 1.68 and 1.67 (s, 6H, 2CH3(4) isoxazole);
13C NMR (101 MHz, DMSO-d6) d (ppm): 161.42 (isoxazole
C3), 161.06 and 159.90 (C‚O, amide), 155.49 (isoxazole
C5), 147.91 (CANO2), 145.83 (pyrazole C3), 144.48 (pyrazole
C5), 120.14 (pyrazole C4), 105.16 and 105.00 (isoxazole C4),
10.32 (isoxazole-CH3(3)), 5.90 (isoxazole-CH3(4)), 144.11,
143.21, 142.68, 138.98, 134.57, 134.08, 131.73, 130.71,
129.81, 128.77, 127.96, 127.73, 127.32, 123.54, 120.54,
119.12, 117.53. Anal. Calcd. for C39H33N9O10S2: C, 54.99;
H, 3.90; N, 14.80; S, 7.53; Found: C, 55.04; H, 3.88; N,
14.85; S, 7.55.
2.2.6. General procedure for reduction of nitro groups
Sodium polysulﬁde solution was prepared from Na2S.9H2O
(2.5 g) with powdered sulfur (0.7 g) dissolved in approximately
100 ml boiling water. Hot sodium polysulﬁde solution was
then added dropwise to a stirred boiling solution of nitro com-
pound (3–6) (2 mmol) in methanol. The reaction mixture was
boiled for 1 h. Then the reaction mixture was cooled and acid-
iﬁed with concentrated HCl. The precipitated product was ﬁl-
tered and dissolved in hot acetone. The hot solution was
ﬁltered to remove unreacted sulfur. Then acetone wasbearing biologically active sulfonamide moiety as potential carbonic anhydrase
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Novel pyrazole-3,4-dicarboxamides bearing biologically active sulfonamide moiety 5evaporated in vacuo to dryness. Finally the crude product was
crystallized from appropriate solvent.
2.2.7. 1-(3-Aminophenyl)-5-phenyl-N3,N4-bis(5-sulfamoyl-
1,3,4-thiadiazol-2-yl)-1H-pyrazole-3,4-dicarboxamide (7)
Synthesized according to the general procedure and the crude
product was puriﬁed by crystallization from EtOH/H2O (2:1).
Yield: 86%; mp: 260–262 C; IR (t, cm1): 3332 and 3284 (NH
and NH2), 3061 (ArCH), 1667 (C‚O, amide), 1605–1411
(C‚C and C‚N), 1343 and 1166 (S‚O); 1H NMR
(400 MHz, DMSO-d6) d (ppm): 13.72 (br, s, 2H, 2CONH),
8.44 and 8.40 (s, 4H, 2SO2NH2), 8.30–7.31 (m, 9H, ArH),
3.88 (br, s, 2H, Ar-NH2);
13C NMR (101 MHz, DMSO-d6) d
(ppm): 164.98 and 164.63 (C‚O, amide), 161.26, 160.95,
160.72 and 160.11 (thiadiazole C-2 and C-5), 147.92
(CANH2), 145.80 (pyrazole C-3), 142.71 (pyrazole C-5),
120.24 (pyrazole C-4), 138.68, 131.13, 130.64, 130.15, 129.61,
128.82, 126.45, 123.61, 117.07. Anal. Calcd. for
C21H17N11O6S4: C, 38.94; H, 2.65; N, 23.79; S, 19.80;
Found: C, 38.88; H, 2.62; N, 23.81; S, 19.77.
2.2.8. 1-(3-Aminophenyl)-5-phenyl-N3,N4-bis(4-sulfamoylphen-
yl)-1H-pyrazole-3,4-dicarboxamide (8)
Synthesized according to the general procedure and the crude
product was puriﬁed by crystallization from EtOH/DMF (3:1).
Yield: 84%; mp: 270–272 C; IR (t, cm1): 3341 and 3248 (NH
and NH2), 3040 (ArCH), 1661 (C‚O, amide), 1620–1494
(C‚C and C‚N), 1314 and 1152 (S‚O); 1H NMR
(400 MHz, DMSO-d6) d (ppm): 11.53 and 10.50 (s,
2H, 2CONH), 7.11 and 7.04 (s, 4H, 2SO2NH2), 7.91–6.25
(m, 17H, ArH), 3.55 (br, s, 2H, Ar-NH2);
13C NMR
(100 MHz, DMSO-d6) d (ppm): 161.54 and 161.34 (C‚O,
amide), 149.38 (CANH2), 146.20 (pyrazole C-3), 142.63 (pyra-
zole C-5), 120.93 (pyrazole C-4), 142.34, 141.39, 139.48,
139.34, 138.55, 130.18, 129.55, 129.50, 128.91, 128.47, 127.15,
127.08, 119.54, 118.69, 115.10, 114.03, 111.89. Anal. Calcd.
for C29H25N7O6S2: C, 55.14; H, 3.99; N, 15.52; S, 10.15;
Found: C, 55.21; H, 4.02; N, 15.57; S, 10.09.
2.2.9. 1-(3-Aminophenyl)-5-phenyl-N3,N4-bis(4-(N-(pyrimidi-
n-2-yl)sulfamoyl)phenyl)-1H-pyrazole-3,4-dicarboxamide (9)
Synthesized according to the general procedure and the crude
product was puriﬁed by crystallization from EtOH/DMF (2:1).
Yield: 83%; mp: 224–226 C; IR (t, cm1): 3356 and 3257 (NH
and NH2), 3039 (ArCH), 1689 and 1628 (C‚O, amide), 1580–
1439 (C‚C and C‚N), 1323 and 1151 (S‚O); 1H NMR
(400 MHz, DMSO-d6) d (ppm): 11.44 (br, s, 2H, 2SO2NH),
11.02 and 10.81 (s, 2H, 2CONH), 8.51 and 8.48 (d, J= 4.5
Hz, 2 · (2H), 4CH, symmetrical pyrimidine H4 and H6),
8.02–6.01 (m, 17H, ArH), 7.02 (t, J= 5.4 Hz, 2 · (1H),
2CH, symmetrical pyrimidine H5), 5,46 (br, s, 2H, ArNH2);
13C NMR (101 MHz, DMSO-d6) d (ppm): 158.34 and 158.21
(C‚O, amide), 157.20 (pyrimidine C2), 156.94 and 153.00
(pyrimidine C4 and C6), 149.58 (CANH2), 143.42 (pyrazole
C3), 142.97 (pyrazole C5), 119.91 (pyrazole C4), 118.53
(pyrimidine C5), 142.42, 139.32, 134.75, 134.31, 129.80,
129.29, 128.84, 128.55, 128.42, 124.86, 115.76, 115.49, 113.00,
112.12, 111.02. Anal. Calcd. for C37H29N11O6S2: C, 56.41;
H, 3.71; N, 19.56; S, 8.14; Found: C, 56.48; H, 3.74; N,
19.57; S, 8.16.Please cite this article in press as: Mert, S. et al., Novel pyrazole-3,4-dicarboxamides
inhibitors. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.22.2.10. 1-(3-Aminophenyl)-N3,N4-bis(4-(N-(3,4-dimethylisox-
azol-5-yl)sulfamoyl)phenyl)-5-phenyl-1H-pyrazole-3,4-dicarbo-
xamide (10)
Synthesized according to the general procedure and the crude
product was puriﬁed by crystallization from methanol. Yield:
87%; mp: 226–228 C; IR (t, cm1): 3399 and 3338 (NH and
NH2), 3035 (ArCH), 2933 (Aliphatic CH), 1694 and 1661
(C‚O, amide), 1589–1476 (C‚C and C‚N), 1333 and 1152
(S‚O); 1H NMR (400 MHz, DMSO-d6) d (ppm): 11.20 and
10.89 (s, 2H, 2CONH), 11.01 (br, s, 2H, SO2NH), 8.09–6.38
(m, 17H, ArH), 3,57 (br, s, 2H, ArNH2), 2.09 (s, 6H,
2CH3(3) isoxazole), 1.67 and 1.66 (s, 6H, 2CH3(4) isoxazole);
13C NMR (101 MHz, DMSO-d6) d (ppm): 161.73 and 160.10
(C‚O, amide), 161.34 (isoxazole C3), 155.89 and 155.83 (isox-
azole C5), 149.59 (CANH2), 143.57 (pyrazole C3), 143.29
(pyrazole C5), 120.34 (pyrazole C4), 104.56 and 104.53 (isoxa-
zole C4), 10.33 (isoxazole-CH3(3)), 5.95 and 5.91 (isoxazole-
CH3(4)), 142.92, 142.76, 139.19, 134.63, 134.17, 129.32,
128.44, 127.95, 127.88, 127.62, 119.45, 119.00, 114.19, 113.02,
112.64, 111.05, 99.51. Anal. Calcd. for C39H35N9O8S2: C,
56.99; H, 4.29; N, 15.34; S, 7.80; Found: C, 57.08; H, 4.33;
N, 15.30; S, 7.78.
2.3. Biological activity evaluation
2.3.1. Hemolysate preparation
Erythrocytes were puriﬁed from fresh human blood, which
was obtained from the University Hospital Blood Center of
Erzurum Atatu¨rk University. Following low speed centrifuga-
tion (1500 rpm for 15 min) and removal of plasma and buffy
coat, the red blood cells were isolated, washed twice with
0.9% NaCl and hemolyzed with 1.5 volumes of ice-cold water.
Ghost and intact cells were then removed by high-speed cen-
trifugation (20,000 rpm for 30 min.) at 4 C and the pH of
the hemolysate adjusted to 8.7 with solid Tris.
2.3.2. Puriﬁcation of carbonic anhydrase isozymes from human
erythrocytes by afﬁnity chromatography
Sepharose-4B L-tyrosine afﬁnity chromatography column was
prepared according to our previous studies (Balseven et al.,
2013; Kasımog˘ulları et al., 2011). The pH-adjusted human
erythrocyte hemolysate was applied to the Sepharose
4B-L-tyrosine-sulfanilamide afﬁnity column pre-equilibrated
with 25 mM Tris–HCl/0.1 M Na2SO4 (pH 8.7). The afﬁnity
gel was washed with 25 mM tris–HCl/22 mM Na2SO4
(pH = 8.7). The human carbonic anhydrase isozymes (hCA I
and hCA II) were eluted with 1.0 M NaCl/25 mM Na2HPO4
(pH 6.3) and 0.1 M NaCH3COO/0.5 M NaClO4 (pH 5.6),
respectively.
During puriﬁcation procedures of hCA I and hCA II, the
absorbency was measured at 280 nm to monitor protein elu-
tion by afﬁnity chromatography. CO2-hydratase activity was
determined in eluted fractions and the active fractions were
collected.
2.3.3. Hydratase and esterase activity assay
2.3.3.1. Hydratase activity assay. Carbonic anhydrase catalyzes
the hydration of carbon dioxide to form bicarbonate and a
proton.
CO2 þH2OHþ þHCO3bearing biologically active sulfonamide moiety as potential carbonic anhydrase
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hydration of CO2 according to the method described by
Wilbur and Anderson (1948).
2.3.3.2. Esterase activity assay. Carbonic anhydrase enzymes
catalyze some non-physiological reactions under in vitro condi-
tions. For instance, it was observed that the puriﬁed enzyme
has esterase activity under in vitro conditions.
Esterase activity of human erythrocyte carbonic anhydrase
was assayed by following the change in absorbance at 348 nm
of 4-nitrophenyl acetate to 4-nitrophenolate ion over a period
of 3 min at 25 C using a spectrophotometer (Verpoorte et al.,
1967).
2.3.4. In vitro inhibition studies
In inhibition studies carbonic anhydrase activity was assayed
by following the change in absorbance at 348 nm of
4-nitrophenylacetate (NPA) to 4-nitrophenylate ion over a
period of 3 min at 25 C using a spectrophotometer according
to the method described by Verpoorte et al. (1967). The enzy-
matic reaction, in a total volume of 1 ml, contained 50 mMCA I
CA II  
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Figure 2 Lineweaver–Burk graphs of the compound 4 on CA I
and CA II.
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enzyme solution. A reference measurement was done by the
same cuvette without enzyme solution. The inhibitory effects
of newly synthesized sulfonamide derivatives on carbonic
anhydrase enzyme activity puriﬁed from human erythrocyte
were tested in triplicate at each concentration used. CA activ-
ities were measured in the presence of different substrate con-
centrations. Control activity in the absence of inhibitor was
assumed to be 100%. For each compound, a percent activity
versus inhibitor concentration graph was plotted. Ki values
of the compounds were calculated by measuring enzyme activ-
ity at three different inhibitor concentrations with ﬁve different
substrate concentrations. Lineweaver–Burk curves (see Fig. 2)
were used for the determination of Ki and inhibition type
(Balseven et al., 2013; Kasımog˘ulları et al., 2011).
3. Results and discussion
3.1. Chemistry
Recently it has been reported that Celecoxib, pyrazole and sul-
fonamide containing antiinﬂammatory agent, was a strong
inhibitor of CA IX and CA II (Weber et al., 2004; Gluszok
et al., 2010). When administered Celecoxib and Valdecoxib
orally to glaucomatous rabbits, it was observed these drugs
lowered the intraocular pressure, suggesting that they may
have utility in the treatment of this disorder (Weber et al.,
2004; Di Fiore et al., 2006). Also some modiﬁcation studies
have made over pyrazole ring for a good selectivity CA IX ver-
sus CA II (Gluszok et al., 2010; Rogez-Florent et al., 2013).
Based on these informations, our study was conducted in order
to design synthesize, characterize and evaluate the biological
activity of novel pyrazole-3,4-dicarboxamides (3–10) which
bearing two sulfonamide scaffolds in the 3 and 4 position of
the pyrazole ring.
Firstly 1-(3-nitrophenyl)-5-phenyl-1H-pyrazole-3,4-dicarb-
oxylic acid (1) was synthesized according to our previous stud-
ies and its carboxyl groups were activated (2) with SOCl2
(Mert et al., 2014). Then novel nitro substitute pyrazole-3,4-
dicarboxamides 3–6 were synthesized from the reaction of acid
dichloride (2) with the 4-aminobenzene sulfonamide (sulfanil-
amide), 5-amino-1,3,4-thiadiazole-2-sulfonamide, sulfadiazine,
and Sulﬁsoxazole, respectively (see Scheme 1 and Table 1).
Acid chloride was reacted with sulfonamide derivatives in the
molar range of 1:4, at reﬂux in THF, leading to the nitro
derivatives (3–6). Then the subsequent reduction of the nitro
group of 3–6 with sodium-polysulﬁde hydrogenation
(Na2S/S/H2O) afforded four novel amine derivatives (7–10).
The general synthetic route shown in Scheme 1 and Table 1
was used to prepare the pyrazole-sulfonamide derivatives
3–10, as reported earlier by our group (Balseven et al., 2013;
Kasımog˘ulları et al., 2011).
The synthesized molecules have been characterized by var-
ious spectral and analytical techniques including FT-IR, 1H
NMR, 13C NMR and Elemental analysis. The infrared (IR)
spectra of all pyrazole-sulfonamide (3–10) derivatives showed
NH or NH2 stretching bands at 3399–3248 cm
1 and showed
sharp peaks for the carbonyl groups in the region between
1694 and 1628 cml. S‚O asymmetric and symmetric stretch-
ing bands were observed at 1378–1314 cml and 1172–
1151 cml, respectively. The compounds 3–6 exhibitedbearing biologically active sulfonamide moiety as potential carbonic anhydrase
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1525 cm1 and 1350 cm1 that belong to NO2 groups.
Aromatic CAH stretching bands were observed in the region
between 3097 and 3036 cm1. The aliphatic CAH stretching
bands of 6 and 10 were observed at 2980 cm1 and
2933 cm1, respectively. The absorption values of other func-
tional groups appeared in the expected regions and they were
consistent with the literature (Kasımog˘ulları et al., 2011;
Sener et al., 2004; Jennings and Lovely, 1991) (see
Experimental for details).
In the 1H NMR spectrum of 3–10 CONH protons were
observed between 13.97 and 10.50 ppm. SO2NH2 peaks
appeared at around 8.4 ppm and 7.2 ppm in thiadiazole
and sulfanilamide containing carboxamides, respectively.
Also SO2NH peaks appeared at around 11 ppm in sterically
hindered sulfonamide containing carboxamides. Signals for
the aromatic protons were observed in the range of 8.49–
6.01 ppm. NH2 protons were observed between 5.46 and
3.55 ppm. In sulfadiazine containing carboxamides, H4 and
H6 protons of the pyrimidine rings were observed between
8.54 and 8.48 ppm as dublets. Also H5 protons of the pyrim-
idine rings appeared at around 7 ppm as triplet or multiplets.
In sulﬁsoxazole containing carboxamides, the methyl protons
bonded the third and fourth position of the isoxazole ring
showed singlet peaks at around 2.1 and 1.7 ppm,
respectively.
In 13C NMR spectra the peaks of C‚O for amides (3–10)
were observed between 165.98 and 158.21 ppm. Other charac-
teristic peaks appeared at expected regions (see Experimental
for details). Also we observed some characteristic peaks related
to sulfonamides which include thiadiazole, pyrimidine and
isoxazole rings. In 13C NMR spectra of 5 and 9, C2 carbons
of pyrimidine ring appeared at 157 ppm. Also C3, C4 and
C5 carbons were observed at 156, 118 and 153 ppm, respec-
tively. Besides in the spectrum of 6 and 10; C3, C4 and C5 car-
bons of isoxazole ring give peaks at 161, 105 and 155 ppm,
respectively. Finally the methyl carbons bonded the third
and fourth position of the isoxazole ring give peaks at around
10.3 ppm and 5.9 ppm. The sum up, 1H NMR, 13C NMR, FT-
IR and elemental analysis results all of the synthesized com-
pounds were in full agreement with the proposed structures
(see Experimental and Table 1).
3.2. Biological activity results
CA inhibitors have been used as antiglaucoma, diuretics, anti-
convulsants, antiobesity, antitumor agents and tumor diagnos-
tic tools (Supuran, 2007). So designing novel CA inhibitors are
very important for discovery of new pharmacological agents
and understanding in detail protein–drug interactions at
molecular level. In the current study, one of the major goal
is to investigate in vitro inhibitory effect of novel sulfonamide
derivatives of pyrazole-3,4-dicarboxamides (3–10) on CA iso-
zymes (hCA I and hCA II). For this aim, CA isozymes
(hCA I and II) were puriﬁed from human erythrocytes by
Sepharose-4B-L-tyrosine afﬁnity chromatography. The puriﬁ-
cation results for hCA I depicted a 67% yield, 670 U/mg speci-
ﬁc activity and approximately 81 puriﬁcation fold. hCA II was
obtained as 84.6% yield, 4230 U/mg speciﬁc activity and
approximately 512 puriﬁcation fold. Additionally, purity of
enzymes was controlled by using SDS–PAGE. PuriﬁedPlease cite this article in press as: Mert, S. et al., Novel pyrazole-3,4-dicarboxamides
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tion step, the effects of novel compounds (3–10) on the esterase
activity of puriﬁed isozymes were investigated as in vitro. All
compounds showed inhibitory effects on both hCA I and
hCA II isoenzymes except compound 5. Compound 5 did
not show any inhibition effects for hCA I while it showed low-
est inhibition effects for hCA II.
Compound 4 has the strongest inhibitory effect on hCA I
and hCA II activities. Ki value of this compound is almost in
nanomolar concentration range (0.056 lM for hCA I and
0.057 lM for hCA II). Also compounds 3 and 7 depicted rel-
atively strong inhibitory effects on both izoenzymes.
According to decreasing inhibition potential on hCA I, com-
pounds can be ranked as 4, 7, 3, 8, 6, 10 and 9. The inhibition
decreasing list of hCA II is in the order of 4, 7, 3, 8, 9, 10, 6 and
5 (see Table 1).
Also structure activity relationships can be drawn with a
comparison between functional groups of the synthesized com-
pounds. In the nitro substituted derivatives (3–6) activity
results can be ranked as 4> 3> 6> 5 both for hCA I and
hCA II. Besides in the amino substituted derivatives (7–10)
activity results can be ranked as 7> 8> 10> 9 for hCA I
also 7> 8> 9  10 for hCA II. Thus, as expected, the results
obtained conﬁrmed the free sulfonamide derivatives (3, 4, 7,
and 8) have a higher inhibition potential on both isozymes.
Furthermore, when comparing the results of the inhibition
between nitro substituted and amino substituted derivatives
generally we can say the reduced products more effective on
the isozymes. If the sterically hindered sulfonamide derivatives
were compared between themselves, the derivatives containing
sulﬁsoxazole generally seen to have stronger inhibitory effects
than the ones containing sulfadiazine. It can be thought that,
sulﬁsoxazole ring has positive contribution to the inhibition
effect.
If we mention the selectivity of the compounds against
isoenzymes, 8 has approximately ten-fold stronger inhibition
potential on hCA II than hCA I. Also compounds 3, 7, and
9 exhibit two-fold stronger inhibition potential on hCA II than
hCA I. So we can say that above mentioned compounds are
more selective inhibitors for hCA II. Unlike other derivatives,
the ones containing sulﬁsoxazole ring (6 and 10) be more selec-
tive against hCA I is quite remarkable.
The inhibition type of the compounds was determined non-
competitively. In another study of our group some pyrazole
sulfonamides were synthesized and the inhibition effects of
these compounds on esterase activities of hCA I and II isoen-
zymes were investigated as in vitro. Our inhibition type results
in this study are consistent with those of our previous study
(Balseven et al., 2013).
4. Conclusions
Up to now, inhibitory effects of various different anions, metal
ions, drugs, phenols and sulfonamides have investigated the
activity of CA isozymes (Ekinci et al., 2007). Inhibition studies
on carbonic anhydrase are important for clariﬁcation of the
mechanisms of enzyme catalysis and designating new drugs.
In this study novel pyrazole-3,4-dicarboxamide (3–10)
derivatives bearing sulfonamide moiety were synthesized and
inhibitory effects of these derivatives on esterase activities of
these isoenzymes have been studied as in vitro. Compound 4bearing biologically active sulfonamide moiety as potential carbonic anhydrase
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8 S. Mert et al.possess remarkable inhibition effects on hCA I and hCA II
and may be used in the generation of potent CAIs.
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